Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Soluble Immune Checkpoints Molecules as Diagnostic and Prognostic Markers in Breast Cancer Patients

NCT06169007 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT06169007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06169007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Soluble Immune Checkpoints Molecules as Diagnostic and Prognostic Markers in Breast Cancer Patients
Lead sponsor
Assiut University
Phase
Observational
Overall status
Unknown status
Start date
May 1, 2024
Completion date
December 1, 2025
Enrollment
84 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer